Abstract: In some aspects, the present disclosure provides methods of aminating an aromatic compound comprising reacting an aminating agent with an aromatic compound in the presence of a rhodium catalyst. In some embodiments, the methods may comprise aminating an aromatic compound which contains multiple different functional groups. The methods described herein may also be used to create bicyclic system comprising reacting an intramolecular aminating agent with an aromatic ring to obtain a second ring containing a nitrogen atom. In another aspect, the methods described herein may also be used to create a cyclic aliphatic cyclic/poly cyclic amine system comprising a reacting an intramolecular aminating agent by insertion into a C(sp3)-H bond.

Abstract: Provided herein are methods for the treatment of poly-cystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Abstract: Embodiments of the present disclosure include compositions and methods related to certain siRNA compositions for the treatment of cancer. In specific embodiments, siRNAs are employed for treatment of cancer, including at least liver cancer. Therapeutic methods, compositions, and kits are encompassed in the disclosure.

Abstract: The present invention relates to non-viral gene therapy methods and compositions for treatment of hyperproliferative disease in humans. More specifically, the invention is directed, in one embodiment, to lipid formulations which form stable liposome structures, capable of efficient in vivo nucleic acid transfer. In other embodiments, methods and compositions are directed to liposome transfer of anti-proliferative nucleic acids, wherein the transfer of the nucleic acids is cell specific via cell specific targeting moieties. The present invention, thus provides non-viral, liposome compositions and methods of gene transfer particularly useful for targeting and treating hyperproliferative disease.

Abstract: Certain embodiments are directed to methods of treating chronic lung diseases in a subject comprising administering to a subject diagnosed with, exhibiting symptoms of, or at risk of developing a chronic lung disease a therapeutically effective amount of a BRD4 inhibitor or a CDK9 inhibitor to the subject.

Abstract: Embodiments of the invention stimulate three levels of beta cell physiology: (i) glucose metabolism, (ii) membrane receptor function, and (iii) transcriptional factors that result in the in vivo formation of beta cells in the pancreas for the purpose of treating diabetes. In certain aspects, the methods include the integration of three levels of cellular physiology: metabolism, membrane receptor function, and gene transcription. The integration of multiple levels of cellular physiology produces a synergistic effect on beta cell formation.

Abstract: A processor architecture utilizing a L3 translation lookaside buffer (TLB) to reduce page walks. The processor includes multiple cores, where each core includes a L1 TLB and a L2 TLB. The processor further includes a L3 TLB that is shared across the processor cores, where the L3 TLB is implemented in off-chip or die-stack dynamic random-access memory. Furthermore, the processor includes a page table connected to the L3 TLB, where the page table stores a mapping between virtual addresses and physical addresses. In such an architecture, by having the L3 TLB with a very large capacity, performance may be improved, such as execution time, by eliminating page walks, which requires multiple data accesses.

Abstract: An approach for change roll out in wireless networks that utilizes a diverse set of features, such as software/hardware configuration, radio parameters, user population, mobility patterns, network topology and automatically identifies the test locations that would improve the predictability between the performance impacts during testing and network-wide deployment. Through automated and effective analysis of a wide variety of features, the approach for change roll out in wireless networks reflects the impacts observed during testing and predicts the performance of the post-test wide-scale deployment.

Abstract: In some aspects, the present disclosure provides novel ligands, which may be used to make novel MRI contrast agents for the detection of zinc. In further aspects, by the present disclosure also provides methods of using as imaging agents and compositions thereof.

Abstract: Disclosed herein are systems and methods for monitoring one or more of cerebral oxygenation and total hemoglobin concentration that can be used to perform accurate, noninvasive measurement of cerebral venous blood oxygen saturation (oxygenation) in neonatal patients. A neonatal cerebral oxygenation detection apparatus comprises a wearable support having a light emitter and an acoustic sensor coupled thereto. The wearable support can be secured onto a head of an infant, and the light emitter can be configured to emit a light toward a superior sagittal sinus of the infant's head. The acoustic sensor can be configured to detect acoustic pressure generated by blood in the superior sagittal sinus when the superior sagittal sinus blood absorbs the light. Cerebral oxygenation and/or total hemoglobin concentration can be determined based on the acoustic pressure detected by the acoustic detector.

Abstract: Embodiments are directed to compositions and methods for treating viral infections.

Abstract: The present invention includes pharmaceutical liposome formulation thereof comprising a N-(2-aminoethyl) ethanolamine (AEEA) and/or active analogs thereof in a liposome, wherein the N-(2-aminoethyl) ethanolamine (AEEA) and/or active analogs thereof are provided in an amount sufficient to treat or reduce scarring of the skin or eye.

Abstract: The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm?1 area/volume to, e.g., increase protein stability; and contacting the droplet with a freezing surface that has a temperature differential of at least 30° C. between the droplet and the surface, wherein the surface freezes the droplet into a thin film with a thickness of less than 500 micrometers and a surface area to volume between 25 to 500 cm?1.

Abstract: The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.

Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.

Abstract: Apparatus and method for optical spectroscopy and/or imaging with a variable fiber offset. An optical probe includes one or more first optical fibers, one or more second optical fibers, and one or more actuators. The first optical fibers are to deliver light to an object. The second optical fibers are to collect light emitted from the object. The actuators are configured to change a distance between the first optical fibers and the second optical fiber while the object is being illuminated by light emitted from the first optical fibers.

Abstract: The present invention includes an apparatus and method of making and using a composition that includes the replacement of electrochemically inactive additives with a conductive and electrochemically active polymer that is attached so as to make an electrical contract to the redox couples of the electrochemically active oxide particles into/from which Lithium is reversibly inserted/extracted in a battery discharge/charge cycle.

Abstract: In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, the target nucleic acid is a nucleic acid that encodes cartilage oligomeric matrix protein. In certain embodiments, the target nucleic acid is a nucleic acid expressed in the growth plate, tendon, or cartilage.

Abstract: Provided herein are methods and compositions for the detection of vulnerable, rupture-prone aneurysms using multi-meric folate conjugated peptides (FCPs). Further provided are methods for treating aneurysms identified to be at risk of rupture.